

Appendix 10. Impact and views Type 4 summary

	A	B	C	D	E	F	G	H	I	J	K
56	Q8. if it is clinically safe for someone should they be given the opportunity?										
57	Answer Choices		Responses								
58		Yes	100.0%	3							
59		Total		3							
60											
61	Q15. In your view, are there any 'groups' that you think might benefit more from nusinersen treatment? (tick all that apply)										
62	Answer Choices		Responses								
63	SMA Type 1		100.0%	3							
64	SMA Type 1 / 2		100.0%	3							
65	SMA Type 2		100.0%	3							
66	SMA Type 2 / 3		100.0%	3							
67	SMA Type 3		100.0%	3							
68	SMA Type 4		100.0%	3							
69	age 0 - 35 months		100.0%	3							
70	age 3 - 7 years		100.0%	3							
71	age 8 - 12 years		100.0%	3							
72	age 13 - 17 years		100.0%	3							
73	age 18 - 25 years		100.0%	3							
74	age 26 years +		100.0%	3							
75	Don't know		33.3%	1							
76		Answers		3							
77											
78	Type 4 age 46-55 years partner										
79	<p>The biggest challenges are lack of mobility and very low levels of energy and the affect this has on both our lives physically and emotionally. Everyday activities such as getting showered and dressed, preparing food and travelling all require assistance and take a lot of effort. My partner (with SMA) cannot manage these simple everyday activities without help and is exhausted upon completion. This affects him emotionally too as he feels he cannot contribute equally in the upbringing of our children and looking after our home.</p>										